Wood Laura S, Lim Zita D
Laura S. Wood.
Zita D. Lim.
Clin J Oncol Nurs. 2025 May 19;29(3):219-229. doi: 10.1188/25.CJON.219-229.
Vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs), alone or in combination with immune checkpoint inhibitors, are part of the standard of care in treating metastatic renal cell carcinoma (mRCC). VEGFR-TKIs are associated with acute, chronic, and potentially dose-limiting toxicities requiring treatment modifications and discontinuations.
This article summarizes evidence-based practices that oncology nurses may use to manage VEGFR-TKI adverse events and improve quality of life in patients with mRCC.
Pivotal clinical trial publications of VEGFR-TKIs in mRCC were reviewed to evaluate the adverse event profile of each drug and effective management strategies.
Patients with mRCC treated with VEGFR-TKIs can benefit from education about potential side effects, consistent monitoring, and early detection of adverse events, as well as appropriate interventions to improve treatment tolerability, adherence, outcomes, and quality of life.
血管内皮生长因子受体酪氨酸激酶抑制剂（VEGFR-TKIs）单独使用或与免疫检查点抑制剂联合使用，是治疗转移性肾细胞癌（mRCC）的标准治疗方案的一部分。VEGFR-TKIs与急性、慢性以及可能的剂量限制性毒性相关，需要调整治疗方案并停药。
本文总结了肿瘤学护士可用于管理VEGFR-TKI不良事件并改善mRCC患者生活质量的循证实践。
回顾了VEGFR-TKIs在mRCC中的关键临床试验出版物，以评估每种药物的不良事件概况和有效的管理策略。
接受VEGFR-TKIs治疗的mRCC患者可从以下方面获益：了解潜在副作用的教育、持续监测和不良事件的早期发现，以及适当的干预措施，以提高治疗耐受性、依从性、治疗效果和生活质量。
